drugset
drugset / Trial / NCT00311415

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

NCT00311415 ↗

Phase 3 Completed 257 enrolled Novartis Vaccines
RandomizedParallel-groupOpen-labelPrevention

Summary

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children

Timeline

Start
2005-10
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Menjugate Vaccine — —

Indications

meningococcal infection